Abstracts tagged "Sjogren’s syndrome and mesenchymal stem cells"

Abstract Number: 13 • 2019 ACR/ARP Annual Meeting
The Effect of Estrogen and Interferon γ on the Immunobiology of Minor Salivary Gland Mesenchymal Stromal Cells
Sara McCoy¹, Jayeeta Giri ² and Jacques Galipeau ³, ¹University of Wisconsin School of Medicine and Public Health, Madison, ²University of Wisconsin, Madison, ³University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Primary Sjӧgren’s syndrome (pSS) is a female-predominant autoimmune disease with peak onset in perimenopause. pSS is characterized by severe ocular and oral sicca, leading…
Abstract Number: 1501 • 2013 ACR/ARHP Annual Meeting
Umbilical Cord Mesenchymal Stem Cells Inhibit The Generation Of T Follicular Helper Cell In Sjogren’s Syndrome
Rui Liu¹, Min Zhou¹, Dinglei Su¹, Xia Li¹ and Lingyun Sun², ¹Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: The immune suppressive properties of mesenchymal stem cells (MSC) have garnered increasing attention over past decades. Human umbilical cord-derived MSC (UC-MSC) share similar immunosuppressive…
Abstract Number: 2556 • 2012 ACR/ARHP Annual Meeting
Allogenic Mesenchymal Stem Cells Transplantation Alleviates Clinical Sjögren’s Syndrome
Lingyun Sun¹, Dandan Wang¹, Junji Xu² and Songlin Wang², ¹Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Salivary Gland Disease Center and Molecular Laboratory for Gene Therapy & Tooth Regeneration, Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, Capital Medical University School of Stomatology, Beijing, China
Background/Purpose: Sjögren's syndrome (SS) is a systemic autoimmune disease that is characterized by dry mouth and dry eyes. Currently, treatment of SS is difficult and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].